Data gathered: November 27
AI Stock Analysis - Adaptive Biotechnologies (ADPT)
Analysis generated August 15, 2024. Powered by Chat GPT.
Adaptive Biotechnologies is a clinical-stage biotechnology company that leverages the infrastructure of the adaptive immune system to develop diagnostic tests and drug discovery applications. The company uses a combination of state-of-the-art technology and advanced artificial intelligence to provide deeper insights into immune system architecture and function, applying these insights to commercial diagnostics and therapeutic products.
Stock Alerts - Adaptive Biotechnologies (ADPT)
 |
Adaptive Biotechnologies | November 26 Price is up by 5.2% in the last 24h. |
|
Adaptive Biotechnologies | November 25 Price is up by 8.1% in the last 24h. |
|
Adaptive Biotechnologies | November 22 Price is up by 5.5% in the last 24h. |
|
Adaptive Biotechnologies | November 20 Insider Alert: PISKEL KYLE is selling shares |
Alternative Data for Adaptive Biotechnologies
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 21 | Sign up | Sign up | Sign up |
| Sentiment | 70 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | 24 | Sign up | Sign up | Sign up |
| Patents | 29 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 77 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,781 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,205 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,247 | Sign up | Sign up | Sign up |
| Twitter Followers | 4,688 | Sign up | Sign up | Sign up |
| Twitter Mentions | 31 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 22 | Sign up | Sign up | Sign up |
| Linkedin Employees | 668 | Sign up | Sign up | Sign up |
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
| Price | $5.73 |
| Target Price | Sign up |
| Volume | 537,360 |
| Market Cap | $823M |
| Year Range | $2.34 - $6.49 |
| Dividend Yield | 0% |
| Analyst Rating | 71% buy |
| Industry | Biotechnology |
In the news
 |
Adaptive Biotechnologies: Making Some ProgressNovember 25 - SeekingAlpha |
 |
Jennison Associates LLC Boosts Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)November 24 - ETF Daily News |
 |
Reviewing Adaptive Biotechnologies (NASDAQ:ADPT) and Tarsus Pharmaceuticals (NASDAQ:TARS)November 22 - ETF Daily News |
|
Head to Head Survey: Adaptive Biotechnologies (NASDAQ:ADPT) & Ginkgo Bioworks (NYSE:DNA)November 20 - ETF Daily News |
|
What is William Blair’s Estimate for ADPT FY2024 Earnings?November 20 - ETF Daily News |
|
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Short Interest UpdateNovember 18 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 46M | 59M | -13M | -32M | -28M | 0.000 |
| Q2 '24 | 43M | 70M | -27M | -46M | -42M | -0.310 |
| Q1 '24 | 39M | 66M | -27M | -48M | -44M | -0.330 |
| Q4 '23 | 43M | 88M | -45M | -69M | -71M | -0.300 |
| Q3 '23 | 34M | 60M | -26M | -50M | -51M | -0.350 |
Insider Transactions View All
| PISKEL KYLE filed to sell 154,330 shares at $5. November 19 '24 |
| Taylor Stacy L filed to sell 139,365 shares at $4.5. August 23 '24 |
| BOBULSKY SUSAN filed to sell 255,265 shares at $3.4. March 6 '24 |
| BOBULSKY SUSAN filed to sell 248,290 shares at $3.4. March 6 '24 |
| ROBINS CHAD M filed to sell 2,619,495 shares at $3.4. March 6 '24 |
Similar companies
Read more about Adaptive Biotechnologies (ADPT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Adaptive Biotechnologies?
The Market Cap of Adaptive Biotechnologies is $823M.
What is the current stock price of Adaptive Biotechnologies?
Currently, the price of one share of Adaptive Biotechnologies stock is $5.73.
How can I analyze the ADPT stock price chart for investment decisions?
The ADPT stock price chart above provides a comprehensive visual representation of Adaptive Biotechnologies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Adaptive Biotechnologies shares. Our platform offers an up-to-date ADPT stock price chart, along with technical data analysis and alternative data insights.
Does ADPT offer dividends to its shareholders?
As of our latest update, Adaptive Biotechnologies (ADPT) does not offer dividends to its shareholders. Investors interested in Adaptive Biotechnologies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Adaptive Biotechnologies?
Some of the similar stocks of Adaptive Biotechnologies are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.